Stock RVNC REVANCE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Real-time Estimate Cboe BZX
Other stock markets
 12:55:20 2024-06-10 pm EDT 		5-day change 1st Jan Change
2.675 USD -0.93% Intraday chart for Revance Therapeutics, Inc. -10.80% -69.45%
May. 10 Needham Adjusts Price Target on Revance Therapeutics to $12 From $18, Maintains Buy Rating MT
May. 10 Piper Sandler Cuts Price Target on Revance Therapeutics to $11 From $20, Maintains Overweight Rating MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Revance to Participate in Upcoming Investor Conferences
BU
Needham Adjusts Price Target on Revance Therapeutics to $12 From $18, Maintains Buy Rating
MT
Piper Sandler Cuts Price Target on Revance Therapeutics to $11 From $20, Maintains Overweight Rating
MT
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY for the Treatment of Cervical Dystonia
AQ
Earnings Flash (RVNC) REVANCE THERAPEUTICS Reports Q1 Revenue $51.9M, vs. Street Est of $56.7M
MT
Revance Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Transcript : Revance Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
BU
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
BU
Revance Therapeutics, Inc. Announces the Commercial Launch of DAXXIFY (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia
CI
Certain Restricted Stock Units of Revance Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-MAY-2024.
CI
Certain Common Stock of Revance Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-MAY-2024.
CI
Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
BU
AbbVie raises annual profit forecast on strong Skyrizi sales
RE
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting
AQ
Northern District Of California Grants Motion To Dismiss Putative Class Action Against Biotech Company And Executives
AQ
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
BU
Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting
CI
Revance Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RVNC Stock
  4. News Revance Therapeutics, Inc.